

1 **Reduction in antibiotic prescribing attainable with a gonococcal vaccine**

2

3 Stephen M. Kissler^{1*}, Moriah Mitchell^{2*}, Yonatan H. Grad¹

4

5 ¹Department of Immunology and Infectious Diseases, Harvard. T.H. Chan School of Public
6 Health, Boston MA, USA

7 ²Department of Epidemiology, Harvard. T.H. Chan School of Public Health, Boston MA, USA

8 * contributed equally

9

10 Correspondence: Yonatan H. Grad (ygrad@hsph.harvard.edu)

11

12 Key words: Gonorrhoea, vaccine, antibiotic prescribing, antibiotic resistance

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Antibiotic prescribing for gonorrhea

13 **Abstract.** We estimated the fraction of antibiotic prescribing in the US attributable to gonorrhea.
14 Gonorrhea contributes to an outsized proportion of antibiotic prescriptions in young adults, males,
15 and in the southern and western US. A gonococcal vaccine could substantially reduce antibiotic
16 prescribing in these populations.

Antibiotic prescribing for gonorrhea

17 **Introduction.**

18 Antibiotic resistance poses a growing threat to human health¹. Antibiotic resistance is driven by
19 the consumption of antibiotics, which exert evolutionary selective pressures on the intended target
20 pathogen and on ‘bystander’ microorganisms². Vaccination has been proposed as a means of
21 reducing the incidence of illnesses that prompt antibiotic prescriptions, thereby reducing down-
22 stream antibiotic resistance³.

23
24 Gonorrhea is the second most prevalent reportable illness in the United States, with nearly
25 600,000 cases reported in 2018⁴, and is a major contributor to morbidity worldwide⁵. The US
26 treatment recommended by the Centers for Disease Control and Prevention (CDC) for gonorrhea
27 is dual therapy with single dose oral azithromycin and intramuscular ceftriaxone⁶. Gonorrhea
28 therefore contributes substantially to antibiotic prescribing.

29
30 There is currently no vaccine licensed for the prevention gonorrhea, though modest vaccine-in-
31 duced protection has been demonstrated via cross-protection from the MeNZB *Neisseria meningi-*
32 *titidis* vaccine and the investigation of the benefit of meningococcal group B vaccine (Bexsero) is
33 ongoing^{7,8}. While the impact an effective gonococcal vaccine could be profound in terms of re-
34 ductions in gonorrhea-associated morbidity, it also has the potential benefit of reducing a large
35 amount of antibiotic prescribing. Such a vaccine might reduce the threat of multi-drug-resistant
36 gonorrhea – a top public health threat according to the CDC¹ – as well as reduce the selective
37 pressures exerted on other bystander organisms during the course of treatment for gonorrhea.
38 However, the extent of impact of a gonococcal vaccine on antibiotic prescribing has not been
39 quantified. Here, we integrate reported cases of gonorrhea in the United States with a large da-
40 tabase capturing outpatient antibiotic prescriptions to estimate the amount of antibiotic prescribing
41 attributable to gonorrhea and thus the reduction in antibiotic prescribing that would be possible
42 with a gonococcal vaccine.

43 **Methods.**

44 Study sample and population.

45 We extracted annual cases of gonorrhea and chlamydia by state, sex, and age group (0–14, 15–
46 19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–54, 55–64, 65+) in the United States from 2015–
47 2018, the most recent years available, from the CDC’s *AtlasPlus* portal⁹. We used the population
48 sizes for each demographic and geographic group, available from the same source, to calculate
49 cases per 1,000 individuals (**Table 1**).

50
51
52 We extracted outpatient antibiotic prescriptions from the Truven MarketScan database¹⁰ over the
53 same timeframe. This database captures all outpatient pharmacy claims from a convenience sam-
54 ple of 19.1–24.3 million individuals (5.9–7.6% of the US population), depending on the month. We
55 linked each antibiotic prescription with the patient’s age, sex, state. Full extraction details are
56 given in the **Supplement**.

57

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Antibiotic prescribing for gonorrhea

58 Next, we estimated the number and proportion of azithromycin prescriptions, ceftriaxone prescrip-
59 tions, and overall antibiotic prescriptions in the US that were attributable to gonorrhea in 2015-
60 2018. The recommended course of azithromycin and ceftriaxone for treating gonorrhea is nor-
61 mally administered under the supervision of a provider upon diagnosis, so these prescriptions are
62 not recorded in the MarketScan outpatient prescriptions data. We therefore added one dose of
63 azithromycin and one dose of ceftriaxone for each reported gonorrhea infection to the outpatient
64 antibiotic prescriptions data extracted from MarketScan. We also accounted for antibiotic pre-
65 scriptions for chlamydia, the most common reportable illness in the US, by adding one dose of
66 azithromycin to the MarketScan outpatient prescriptions data for each reported chlamydia case.
67 This is a conservative choice, since chlamydia may be treated by a single supervised dose of
68 azithromycin (recommended) or a 7-day course of doxycycline. By assuming that all cases of
69 chlamydia prompt an azithromycin dose, this will lead to an over-estimate of the number of azithro-
70 mycin prescriptions that are actually given, yielding more conservative estimates of the relative
71 impact of a gonococcal vaccine on azithromycin prescribing.

72
73 For the years 2015–2018, we calculated the percent and total number of azithromycin prescrip-
74 tions, ceftriaxone prescriptions, and total antibiotic prescriptions per 1,000 people that were at-
75 tributable to gonorrhea. For 2018, when gonorrhea incidence was at its highest level in over a
76 decade, we calculated the same statistics stratified by age, sex, and HHS region¹¹.

77
78 **Results.**

79 There were 1.79 reported cases of gonorrhea per 1,000 individuals in the United States in 2018.
80 These accounted for 1.5% of all azithromycin prescriptions, 23.7% of all ceftriaxone prescriptions,
81 and 0.53% of all antibiotic prescriptions of any type given in 2018 (**Table 1**). The incidence of
82 gonorrhea has been rising steadily, increasing by a factor of 1.5 between 2015 and 2018. Mean-
83 while, overall antibiotic prescribing rates have fallen, so that the proportion of antibiotic prescrip-
84 tions due to gonorrhea has increased even faster than the increase in gonorrhea incidence alone
85 would suggest. Reported gonorrhea cases are mainly concentrated in young adults. There were
86 7.12 cases of gonorrhea reported per 1,000 individuals between the ages of 20 and 24 in 2018,
87 accounting for 2.38% of all antibiotic prescriptions given in that age group. Reported gonorrhea
88 cases were less frequent in females than in males (1.46 vs. 2.13 cases per 1,000 individuals in
89 2018, respectively). Reported gonorrhea cases in 2018 were lowest in the northeast (1.07 cases
90 per 1,000 people in HHS Region 1, Boston) and highest in the southeast (2.06 cases per 1,000
91 people in HHS Region 4, Atlanta). However, gonorrhea-related antibiotic prescriptions accounted
92 for the greatest share of overall antibiotic prescriptions in the west (0.72% of all antibiotic pre-
93 scriptions in HHS Region 9, San Francisco) due to a relatively high rate of gonorrhea infections
94 and a relatively low rate of antibiotic prescribing for other conditions. A vaccine could prevent
95 some fraction of the antibiotic prescriptions associated with gonorrhea cases. Such a vaccine
96 would likely have the greatest impact on antibiotic prescribing in young adults, in males, and in
97 the southern and western US.

98
99 **Discussion.**

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Antibiotic prescribing for gonorrhea

100 We have estimated the share of antibiotic prescribing in the United States attributable to gonor-
101 rhea infections and have identified the sub-populations in which antibiotic prescribing would likely
102 decline the most with an effective gonococcal vaccine. Gonorrhea incidence and associated gon-
103 orrhea-related antibiotic prescribing are especially variable between age groups, with the highest
104 incidence and highest associated prescribing rates in young adults. Since overall antibiotic pre-
105 scribing rates are lowest in this same age group, a gonococcal vaccine would yield an outsized
106 benefit in this age group in terms of the fraction of antibiotic prescriptions averted. Reducing an-
107 tibiotic prescribing in demographic groups that otherwise receive few antibiotics may be an espe-
108 cially effective strategy for combatting antibiotic resistance, since a given antibiotic course is ex-
109 pected to contribute more to resistance in an individual who receives few other prescriptions than
110 in an individual who already receives many¹². Taken together, these findings suggest that a gon-
111 ococcal vaccine could lead to a substantial reduction in antibiotic prescribing, helping to combat
112 the rise in antibiotic resistance.

113
114 Our findings align with others that have documented higher rates of gonorrhea in the southern
115 United States, in males, and in young adults⁴. Similarly, elevated rates of antibiotic prescribing in
116 the southern United States and in children and older adults have been documented¹³. Gonorrhea
117 incidence has been rising rapidly over the past decade along with rates of antibiotic resistance in
118 gonorrhea. We anticipate that this trend will continue, making gonorrhea account for an even
119 larger share of antibiotic prescriptions and increasing the potential benefit of a gonococcal vaccine
120 for reducing both gonorrhea-related morbidity and associated antibiotic prescribing.

121
122 The ultimate impact of a gonococcal vaccine will depend on the vaccine's efficacy and its uptake
123 in the population. Prioritizing vaccination in young adults would likely have the greatest benefits
124 for both reductions in morbidity and reductions in antibiotic prescribing. Potential reductions in
125 antibiotic prescribing should be considered when assessing the cost-effectiveness of a gonococ-
126 cal vaccine. While we have focused on vaccination, other measures to reduce gonorrhea inci-
127 dence, such as increased condom use, should also lead to a downstream reduction in antibiotic
128 prescribing. We have focused on gonorrhea incidence in the United States, but we anticipate that
129 a gonococcal vaccine would similarly lead to substantial reductions in antibiotic prescribing world-
130 wide.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Antibiotic prescribing for gonorrhea

	Cases/1000 people		Azithromycin		Ceftriaxone		Total antibiotics	
	Rx/1000 people	Pct. due to gonorrhea	Rx/1000 people	Pct. due to gonorrhea	Rx/1000 people	Pct. due to gonorrhea	Rx/1000 people	Pct. due to gonorrhea
Year								
2015	1.23	0.83	148	6.3	19.5	728	0.34	
2016	1.45	1.02	142	6.7	21.4	730	0.40	
2017	1.70	1.30	131	7.3	23.3	706	0.48	
2018	1.79	1.50	119	7.6	23.7	680	0.53	
Age (2018)								
0-14	0.05	0.06	87	0.4	11.4	762	0.01	
15-19	4.32	3.32	130	25.9	16.7	712	1.21	
20-24	7.12	5.21	137	36.6	19.4	598	2.38	
25-29	5.53	4.83	115	20.2	27.3	565	1.96	
30-34	3.66	3.06	120	11.2	32.7	621	1.18	
35-39	2.28	1.81	126	6.3	36.0	658	0.69	
40-44	1.37	1.09	125	3.8	36.5	653	0.42	
45-54	0.74	0.58	127	1.9	38.5	665	0.22	
55-64	0.29	0.21	136	0.9	30.5	739	0.08	
65+	0.05	0.03	171	3.8	1.2	797	0.01	
Sex (2018)								
F	1.46	1.04	140	8.8	16.6	806	0.36	
M	2.13	2.19	97	6.3	33.9	549	0.78	
HHS Region (2018)								
1 (Boston)	1.07	1.11	96	6.1	17.4	585	0.37	
2 (New York City)	1.60	1.27	126	7.4	21.8	714	0.45	
3 (Washington, D.C.)	1.46	1.31	112	7.1	20.7	677	0.43	
4 (Atlanta)	2.06	1.48	139	8.2	25.1	769	0.54	
5 (Chicago)	1.81	1.65	109	7.5	24.2	654	0.55	
6 (Dallas)	1.92	1.32	145	7.9	24.4	779	0.49	
7 (Kansas City)	1.98	1.93	103	7.7	25.8	635	0.62	
8 (Denver)	1.37	1.58	86	7.3	18.7	553	0.49	
9 (San Francisco)	1.96	1.89	103	8.0	24.5	546	0.72	
10 (Seattle)	1.46	2.04	72	7.0	21.0	479	0.61	

Table 1. Gonorrhea cases and antibiotic prescribing rates per 1,000 people in the United States.

Rx=prescriptions; pct=percent.

131
132
133
134

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Antibiotic prescribing for gonorrhoea

135 **Funding.** The project was supported by funding from the Wellcome Trust.

136

137 **Conflicts of interest.** YHG has received consulting income from Quidel, Merck, and GSK, re-
138 search support from Merck and Pfizer, and is on the scientific advisory board of Day Zero Diag-
139 nostics.

Antibiotic prescribing for gonorrhea

References

- 140 1. Centers for Disease Control and Prevention. *Antibiotic Resistance Threats in the United*
141 *States*. Atlanta, GA; 2019. doi:CS239559-B
- 142 2. Tedijanto C, Olesen SW, Grad YH, Lipsitch M. Estimating the proportion of bystander
143 selection for antibiotic resistance among potentially pathogenic bacterial flora. *Proc Natl*
144 *Acad Sci*. 2018;115(51):E11988-E11995. doi:10.1073/pnas.1810840115
- 145 3. Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance:
146 Primary and secondary effects. *Proc Natl Acad Sci*. 2018;115(51):12896-12901.
147 doi:10.1073/pnas.1721095115
- 148 4. Centers for Disease Control and Prevention. Gonorrhea. Sexually transmitted disease
149 surveillance 2018. [https://www.cdc.gov/std/stats18/gonorrhea.htm#:~:text=Gonorrhea—](https://www.cdc.gov/std/stats18/gonorrhea.htm#:~:text=Gonorrhea—United States,the historic low in 2009. Published 2020. Accessed December 7, 2020.)
150 *United States,the historic low in 2009*. Published 2020. Accessed December 7, 2020.
- 151 5. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis
152 and syphilis: global prevalence and incidence estimates, 2016. *Bull World Health Organ*.
153 2019;97(8):548-562P. doi:10.2471/BLT.18.228486
- 154 6. Centers for Disease Control and Prevention. Gonococcal Infections. 2015 STD Treatment
155 Guidelines. <https://www.cdc.gov/std/tg2015/gonorrhea.htm>. Published 2020. Accessed
156 December 7, 2020.
- 157 7. Unemo M, Sikora AE. Proof of principle for effectiveness of a gonorrhoea vaccine. *Nat*
158 *Rev Urol*. 2017;14(11):643-644. doi:10.1038/nrurol.2017.139
- 159 8. National Institute of Allergy and Infectious Diseases (NIAID). *Safety and Efficacy Study of*
160 *Meningococcal Group B Vaccine RMenB+OMV NZ (Bexsero) to Prevent Gonococcal*
161 *Infection.*; 2020.
- 162 9. Centers for Disease Control and Prevention. NCHHSTP AtlasPlus.
163 <https://www.cdc.gov/nchhstp/atlas/>. Published 2020. Accessed December 7, 2020.
- 164 10. IBM Watson Health. *IBM MarketScan Research Databases for Life Sciences*
165 *Researchers*. Somers, NY, USA; 2019.
- 166 11. U.S. Department of Health and Human Services. Regional Offices.
167 <https://www.hhs.gov/about/agencies/iea/regional-offices/index.html>. Published 2017.
- 168 12. Olesen SW, Barnett ML, MacFadden DR, et al. The distribution of antibiotic use and its
169 association with antibiotic resistance. *Elife*. 2018;7. doi:10.7554/eLife.39435
- 170 13. Sanchez G V., Fleming-Dutra KE, Roberts RM, Hicks LA. Core Elements of Outpatient
171 Antibiotic Stewardship. *MMWR Recomm Reports*. 2016;65(6):1-12.
172 doi:10.15585/mmwr.rr6506a1
- 173
- 174

Antibiotic prescribing for gonorrhea

175 **Supplement.**

176

177 Extracting antibiotic claims from the MarketScan database. To extract antibiotic prescribing rates
178 from the MarketScan database, we began by extracting the age, sex, state of enrollment, and
179 member identification number for every person with a full month of insurance enrollment for each
180 month between January 2015 and December 2018. **Supplemental Table 1** lists the number of
181 members enrolled in each month and the proportion of the US population represented. For each
182 member in each month, we then extracted all associated antibiotic claims. Antibiotics were iden-
183 tified by the National Drug Code (NDC) number using a lookup file containing the therapeutic
184 class and drug name provided by Truven MarketScan. To estimate the annual *per capita* antibiotic
185 prescribing rate, we divided the total number of antibiotics prescribed in a given year by the total
186 number of member-months in that year (*i.e.*, the sum of the number of members enrolled across
187 all months in that year) and multiplied by 12. Multiplying this quantity by 1,000 yielded the number
188 of antibiotic prescriptions per 1,000 people in that year. We performed these extractions for
189 azithromycin prescriptions, ceftriaxone prescriptions, and all antibiotic prescriptions.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Antibiotic prescribing for gonorrhea

Year	Month	Members (millions)	Percent of US population
2015	1	24.3	7.61
	2	24.3	7.60
	3	24.3	7.58
	4	24.2	7.56
	5	24.1	7.54
	6	24.1	7.51
	7	24.0	7.50
	8	24.0	7.46
	9	23.9	7.45
	10	23.9	7.44
	11	23.8	7.42
	12	23.8	7.39
2016	1	24.1	7.49
	2	24.1	7.49
	3	24.1	7.48
	4	24.1	7.47
	5	23.9	7.42
	6	24.0	7.42
	7	23.9	7.41
	8	23.9	7.38
	9	23.8	7.36
	10	23.7	7.33
	11	23.6	7.30
	12	23.5	7.27
2017	1	19.8	6.12
	2	19.8	6.11
	3	19.8	6.10
	4	19.7	6.08
	5	19.7	6.06
	6	19.6	6.05
	7	19.6	6.02
	8	19.5	6.01
	9	19.5	5.99
	10	19.5	5.98
	11	19.2	5.91
	12	19.2	5.89
2018	1	21.1	6.48
	2	21.1	6.48
	3	21.1	6.46
	4	21.0	6.45
	5	21.0	6.43
	6	20.9	6.41
	7	20.9	6.39
	8	20.9	6.38
	9	20.8	6.37
	10	20.7	6.34
	11	20.7	6.33
	12	20.6	6.30

190
191
192
193
194

Supplemental Table 1. Number of Insurance members represented in the MarketScan database. The percent of the US population represented in the MarketScan data is calculated using the monthly resident population of the United States as reported by the United States Census Bureau (<https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-total.html>)